About this trial
Rationale Acute respiratory distress syndrome (ARDS) is a frequent cause of hypoxemic respiratory failure with a mortality rate of approximately 30%. The identification of ARDS phenotypes, based on focal or non-focal lung morphology, can be helpful to better target mechanical ventilation strategies of individual patients. Lung ultrasound (LUS) is a non-invasive tool that can accurately distinguish 'focal' from 'non-focal' lung morphology. The investigators hypothesize that LUS-guided personalized mechanical ventilation in ARDS patients will lead to a reduction in 90-day mortality compared to conventional mechanical ventilation.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Admitted to a participating ICU,
invasively ventilated and
fulfil the Berlin criteria for moderate or severe ARDS.
Disqualifiers
Age under 18,
participation in other interventional studies with conflicting endpoints,
conditions in which LUS is not feasible or possible (e.g. subcutaneous emphysema, morbid obesity or wounds),
mechanical ventilation for longer than 7 consecutive days in the past 30 days,
Trial design
Parallel
Treatments tested in this trial
Personalized ventilation
Other interventionPatients who are randomized for personalized ventilation with FOCAL ARDS will receive the following ventilator settings: * Positive end-expiratory pressure (PEEP) ≤ 9 cm water (H2O) * Tidal volume: 6 to 8 mL/kg predicted body weight (PBW) * Daily prone positioning LUS will be repeated every 48-72 hours in supine position for the focal ARDS patients to assess whether they have developed non-focal ARDS during admission. In that case, patients will from then on be treated according non-focal personalized treatment protocol. Patients who are randomized for personalized ventilation with Non-FOCAL ARDS will receive the following ventilator settings: * PEEP ≥ 15 cm H2O * Tidal volume: 4 to 6 mL/kg PBW * Daily recruitment maneuver
Standard care
Other interventionPatient who are randomized in the control group will receive standard care * Tidal volume: 6 mL/kg PBW * PEEP and FiO2 according to the low PEEP and high fraction of inspired oxygen (FiO2) table of the AlVEOLI study * Prone positioning if the Partial Pressure of Oxygen (PaO2) /FiO2 ratio is \< 150 mmHg
Treatment groups
Trial outcomes
Primary outcomes
All-cause mortality
Any death during ICU- or hospital-stay at day 90
Secondary outcomes
All-cause mortality
Any death during ICU- or hospital-stay at day 28
Ventilator free days
Duration of ventilation in survivors
ICU length of stay
Length of stay in the intensive care unit
ICU mortality
Mortality in the ICU
Sponsors and contacts
Click on the lead sponsor to view all of their trials.